ZyVersa Therapeutics (ZVSA) Competitors $0.15 +0.00 (+2.39%) As of 08/15/2025 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. SPRC, ELAB, PCSA, PWUP, ENVB, PTN, GLMD, CANF, ADXS, and ADTXShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include SciSparc (SPRC), PMGC (ELAB), Heatwurx (PCSA), PowerUp Acquisition (PWUP), Enveric Biosciences (ENVB), Palatin Technologies (PTN), Galmed Pharmaceuticals (GLMD), Can-Fite BioPharma (CANF), Ayala Pharmaceuticals (ADXS), and Aditxt (ADTX). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Its Competitors SciSparc PMGC Heatwurx PowerUp Acquisition Enveric Biosciences Palatin Technologies Galmed Pharmaceuticals Can-Fite BioPharma Ayala Pharmaceuticals Aditxt ZyVersa Therapeutics (NASDAQ:ZVSA) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings. Which has more volatility & risk, ZVSA or SPRC? ZyVersa Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Does the media prefer ZVSA or SPRC? In the previous week, ZyVersa Therapeutics had 4 more articles in the media than SciSparc. MarketBeat recorded 5 mentions for ZyVersa Therapeutics and 1 mentions for SciSparc. SciSparc's average media sentiment score of 1.08 beat ZyVersa Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media. Company Overall Sentiment ZyVersa Therapeutics Neutral SciSparc Positive Do institutionals & insiders have more ownership in ZVSA or SPRC? 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ZVSA or SPRC more profitable? SciSparc's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -109.54% -43.95% SciSparc N/A N/A N/A Which has better earnings and valuation, ZVSA or SPRC? SciSparc has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$9.41MN/AN/ASciSparc$1.31M1.82-$6.28MN/AN/A SummarySciSparc beats ZyVersa Therapeutics on 8 of the 9 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23M$3.10B$5.69B$9.81BDividend YieldN/A2.23%3.79%4.07%P/E RatioN/A20.8931.0525.11Price / SalesN/A363.22466.03115.19Price / CashN/A42.3037.4059.05Price / Book0.058.659.096.18Net Income-$9.41M-$54.65M$3.26B$265.11M7 Day Performance-9.18%6.56%7.31%4.19%1 Month Performance-50.40%7.53%5.43%1.99%1 Year Performance-94.52%13.69%30.60%23.75% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.7186 of 5 stars$0.15+2.4%N/A-94.9%$1.23MN/A0.002News CoverageGap DownSPRCSciSparc1.0098 of 5 stars$5.17-3.2%N/A-46.2%$2.74M$1.31M0.004Positive NewsELABPMGC1.025 of 5 stars$1.92-0.8%N/A-99.5%$2.64M$1.71M0.0018Short Interest ↓Gap UpPCSAHeatwurx3.283 of 5 stars$0.22-0.9%$2.00+805.0%-83.5%$2.63MN/A-0.1020News CoveragePositive NewsShort Interest ↓PWUPPowerUp AcquisitionN/A$0.34+0.8%N/A-96.6%$2.61MN/A0.00N/AHigh Trading VolumeENVBEnveric Biosciences2.8365 of 5 stars$1.06-3.2%$10.00+847.9%-84.8%$2.61MN/A-0.0320News CoveragePositive NewsEarnings ReportUpcoming EarningsPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap UpHigh Trading VolumeGLMDGalmed Pharmaceuticals1.9555 of 5 stars$1.44-0.7%N/A-60.0%$2.38MN/A-0.0920News CoverageShort Interest ↓Gap DownCANFCan-Fite BioPharma1.9774 of 5 stars$0.67-3.8%$14.00+1,989.6%-73.9%$2.37M$674K-0.378Short Interest ↑ADXSAyala PharmaceuticalsN/A$0.05+24.4%N/A+164.7%$2.17M$3.24M-0.0120Gap DownADTXAditxtN/A$1.02-10.2%N/A-100.0%$2.15M$130K0.0060News CoverageEarnings ReportUpcoming Earnings Related Companies and Tools Related Companies SPRC Alternatives ELAB Alternatives PCSA Alternatives PWUP Alternatives ENVB Alternatives PTN Alternatives GLMD Alternatives CANF Alternatives ADXS Alternatives ADTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access